Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, will host a conference call and webcast on August 7, 2025, at 4:30 p.m. ET to discuss Q2 2025 financial results and provide a corporate update. The company is developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough.

Investors can join via phone at (877) 870 4263 (domestic) or (412) 317 0790 (international). A webcast will be available in the 'Investors & News' section of TreviTherapeutics.com, with a 30-day replay option.

Conference call and webcast to be held at 4:30 p.m. ET 

NEW HAVEN, Conn., July 31, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended June 30, 2025.

To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event. 

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. 

Chronic cough is a highly prevalent condition, impacting up to 85% of patients with IPF. There are ~150,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients.

Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them. 

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. 

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.  

Investor Contact 
Jonathan Carlson 
Trevi Therapeutics, Inc. 
(203) 654 3286 
carlsonj@trevitherapeutics.com  

Media Contact 
Rosalia Scampoli 
914-815-1465 
rscampoli@marketcompr.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-second-quarter-2025-financial-results-and-provide-a-corporate-update-on-august-7-2025-302518709.html

SOURCE Trevi Therapeutics, Inc.

FAQ

When will Trevi Therapeutics (TRVI) report Q2 2025 earnings?

Trevi Therapeutics will report Q2 2025 earnings on Thursday, August 7, 2025, at 4:30 p.m. ET via conference call and webcast.

What is Trevi Therapeutics' main drug candidate?

Trevi's investigational therapy Haduvio™ (oral nalbuphine ER) is being developed for chronic cough in patients with IPF, non-IPF ILD, and refractory chronic cough.

How can investors access Trevi Therapeutics' Q2 2025 earnings call?

Investors can join via phone at (877) 870 4263 (domestic) or (412) 317 0790 (international), or watch the webcast on TreviTherapeutics.com's 'Investors & News' section.

What conditions is Haduvio being developed to treat?

Haduvio is being developed to treat chronic cough in three conditions: idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC).